Skip to main content

Published locations for Apixaban prevails in study of 163,000 DOAC users

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Apixaban prevails in study of 163,000 DOAC users

User login

  • Reset your password
  • /content/apixaban-prevails-study-163000-doac-users
  • /familypracticenews/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /internalmedicinenews/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac
  • /vascularspecialistonline/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac
  • /ecardiologynews/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /cardiology/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /internalmedicine/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /neurology/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /familymedicine/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac-users
  • /clinicalneurologynews/article/163516/acc-conference-coverage/apixaban-prevails-study-163000-doac